[HIGHLIGHTS] Cognitive decline slowed down by 35%, Alzheimer's treatment "inflection point" has arrived?

Eli Lilly said it will submit a marketing application for donakimab to the U.S. Food and Drug Administration (FDA) this quarter.

If approved, donagumab would be the third monoclonal antibody in the United States to treat Alzheimer's disease. The first two, adducamimab and lencanezumab, received marketing approval from the FDA in June 2021 and January this year, respectively. The main impact of the clinical trials of donasumab is "optimistic", that is, people not only see Alzheimer's Disease as a disease, but also a disease that can and must be treated.